GPCR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 113240 min ago

@ $46.21

Išleistas: 14 vas. 2024 @ 19:06

Grąža: -15.62%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -4.71 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs...

Stats
Šios dienos apimtis	595 285
Vidutinė apimtis	583 637
Rinkos kapitalizacija	1.82B
EPS	$-0.620 ( 2023-11-14 )
Kita pelno data	( $-0.210 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.05
ATR14	$0.0680 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Fmr Llc	Buy	0
2024-03-15	Lin Xichen	Buy	213 486	Stock Option (right to buy)
2024-03-15	Bach Mark Allen	Buy	65 352	Stock Option (right to buy)
2024-03-15	Ma Yingli	Buy	91 494	Stock Option (right to buy)
2024-03-15	Yoon Jun	Buy	148 134	Stock Option (right to buy)

INSIDER POWER
30.42
Last 43 transactions
Buy: 9 065 015 \| Sell: 6 065 489

Tūris Koreliacija

Ilgas: 0.17 (neutral)

Trumpas: -0.80 (moderate negative)

Signal:(59.554) Neutral

Structure Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Structure Therapeutics Koreliacija - Valiuta/Žaliavos

0.49
( neutral )

0.59
( weak )

0.00
( neutral )

0.16
( neutral )

-0.21
( neutral )

-0.51
( weak negative )

Structure Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2023
Pajamos:	$0
Bruto pelnas:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2022
Pajamos:	$0
Bruto pelnas:	$-623 258 (0.00 %)
EPS:	$-1.400

Financial Reports:

No articles found.

Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.